Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Resource Type

CF Research News

Authors

Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.

References

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21

Document

CF Research News Article [1]

Link

Scientific Abstract [2]

Date

Sunday, February 5, 2017

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [3]

Source URL:https://www.ecfs.eu/resource-article/cf-research-news/assessment-safety-and-efficacy-long-term-treatment-combination

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/Konstan%202017_for%20CFRN%20%281%29_0.pdf [2] https://www.ncbi.nlm.nih.gov/pubmed/?term=Assessment%20of%20safety%20and%20efficacy%20of%20long-term%20treatment%20with%20combination%20lumacaftor%20and%20ivacaftor%20therapy%20in%20patients%20with%20cystic%20fibrosis%20homozygous%20for%20the%20F508del-CFTR%20mutation%20%28PROGRESS%29%3A%20a%20phase%203%2C%20extension%20study [3] https://www.ecfs.eu/resource-guideline-type/other-guidelines